Hermetica Superfood Encyclopedia
The Short Answer
Gloriosa superba contains colchicine and structurally related alkaloids (gloriosine, 2-desmethyl colchicine) that disrupt microtubule polymerization by binding to tubulin dimers, exerting anti-inflammatory, antimitotic, and antipyretic effects. In vitro studies demonstrate methanolic seed extracts achieve an IC₅₀ of 19.52 µg/mL against MDA-MB-231 breast cancer cells, comparable in potency to doxorubicin, while tuber extracts produce a 20 mm inhibition zone against multidrug-resistant Staphylococcus aureus.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordGloriosa superba benefits and safety
Gloriosa superba — botanical close-up
Health Benefits
**Antipyretic Activity**
Traditional use across Madagascar (mora) and Yoruba medicine (ewe aje) for fever reduction is supported by phytochemical evidence; colchicine and salicylic acid in rhizomes contribute to fever-suppressing mechanisms through inhibition of prostaglandin synthesis and neutrophil chemotaxis.
**Antibacterial Effects**
Aqueous and methanolic tuber extracts demonstrated a 20 mm inhibition zone against multidrug-resistant Staphylococcus aureus (MRSA) in disc diffusion assays, suggesting clinically relevant antibacterial potential driven by phenolic compounds and alkaloid fractions.
**Anticancer Potential**
Methanolic seed extracts showed 60–80% inhibition of MDA-MB-231 breast cancer cells at 50 µg/mL concentration (IC₅₀ = 19.52 µg/mL), with colchicine's antimitotic action on tubulin polymerization as the primary mechanism.
**Anti-inflammatory and Gout Relief**: Colchicine, present at 2
12–7.58 mg/g in tubers, inhibits neutrophil motility and NLRP3 inflammasome activation, the same pathway exploited by pharmaceutical-grade colchicine in treating acute gout and familial Mediterranean fever.
**Antiparasitic and Pediculicidal Use**
Traditional application of tuber paste for head lice (Pediculus humanus capitis) is reported across African and South Asian ethnobotanical records, with alkaloid content implicated in disrupting arthropod nervous system function.
**Enzyme Inhibition**: G
superba extracts demonstrated 90% inhibition of lipoxygenase (an enzyme central to the arachidonic acid inflammatory cascade) and 83.50% inhibitory effect on acetylcholinesterase, suggesting neuroprotective and anti-inflammatory pharmacodynamics.
**Antidiabetic Activity**
Phytochemical fractions including flavonoids, saponins, and sterols have shown antidiabetic effects in preliminary in vitro models, likely through alpha-glucosidase inhibition and insulin sensitization, though human data remain absent.
Origin & History
Natural habitat
Gloriosa superba is native to tropical and southern Africa and Asia, thriving in well-drained sandy or loamy soils in humid, warm climates across sub-Saharan Africa, Madagascar, India, and Sri Lanka. The plant grows as a climbing perennial via underground tubers (rhizomes) and is found in forest margins, grasslands, and disturbed habitats from sea level to approximately 2,500 meters elevation. It is commercially cultivated in India—particularly in Tamil Nadu, Karnataka, and West Bengal—for extraction of colchicine, an alkaloid of significant pharmaceutical value.
“Gloriosa superba has been employed in African, South Asian, and Malagasy traditional medicine systems for centuries, with documented uses spanning antipyretic treatment (known as mora in Malagasy traditional practice), sexually transmitted infection management including gonorrhea, and ectoparasite control for head lice under the Yoruba name ewe aje. In Ayurvedic medicine, the plant (known as Kalihari or Agnishikha) appears in classical texts as a treatment for skin diseases, snake bite, and abortifacient applications, reflecting awareness of its potent biological activity. Across sub-Saharan African ethnobotany, the tuber is applied topically for arthritis, gout, and wound healing, and internally—in very small quantities—as an antipyretic and anthelmintic, with healers exercising considerable caution given recognition of its toxicity. The plant holds cultural significance in India, where it is the national flower of Zimbabwe and the state flower of Tamil Nadu, and has been commercially cultivated since the 1980s as a primary source of pharmaceutical-grade colchicine for global markets.”Traditional Medicine
Scientific Research
The evidence base for Gloriosa superba consists almost entirely of in vitro assays and phytochemical characterization studies, with no published human clinical trials identified in peer-reviewed literature as of 2024. Key in vitro findings include antibacterial inhibition zones of 20 mm against MRSA, anticancer IC₅₀ values of 19.52 µg/mL against MDA-MB-231 cells in MTT assays, and enzyme inhibition rates of 90% (lipoxygenase) and 83.50% (acetylcholinesterase) at defined concentrations. Population-level phytochemical surveys across 32 Indian accessions have quantified tuber colchicine content at 2.12–7.58 mg/g, providing robust agronomic data but limited translational clinical insight. The gap between in vitro bioactivity data and human clinical outcomes remains substantial; the plant's high toxicity potential at even modest doses severely constrains the feasibility of dose-escalation clinical trials.
Preparation & Dosage
Traditional preparation
**Traditional Rhizome Paste (Topical)**
Freshly ground tuber paste applied externally to the scalp for head lice or to joints for rheumatic pain; exact concentrations unstandardized and historically variable by practitioner.
**Aqueous Extract (Research Setting)**
30–60 mg/mL in experimental in vitro assays; no validated human dose established
Tested at .
**Methanolic Extract (Research Setting)**
Seed extracts used at 50 µg/mL in anticancer MTT assays achieving 60–80% cancer cell inhibition; not a consumer-available form.
**Colchicine Pharmaceutical Derivative**
2 mg/day for gout prophylaxis under medical supervision—this is NOT equivalent to consuming G
Pharmaceutical colchicine (derived from Colchicinum autumnale or G. superba) is dosed at 0.5–1.. superba plant material.
**CRITICAL SAFETY NOTE**
No safe supplemental dose of G. superba rhizome or seed has been established for human consumption. The narrow therapeutic index of colchicine (toxic dose approaches therapeutic dose) makes self-dosing with whole plant material highly dangerous and is not recommended outside of controlled pharmaceutical contexts.
Nutritional Profile
Gloriosa superba is not a nutritional food ingredient and provides no meaningful macronutrient contribution in medicinal use contexts. Its primary phytochemical significance lies in alkaloids: colchicine at 2.12–7.58 mg/g in tubers and up to 0.7–0.9% dry weight in seeds, alongside gloriosine, 2-desmethyl colchicine, and α-lumicolchicine. Secondary metabolites identified by GC-MS include flavonoids, saponins, sterols (including β-sitosterol), phenolic acids (salicylic acid, benzoic acid), resinous substances, and colchicosides (glycosidic forms of colchicine), with seeds containing 17 identified bioactive compounds compared to 9 in tubers. Bioavailability of colchicine from plant matrix is expected to be variable and dependent on extraction solvent polarity, with methanolic and ethyl acetate fractions yielding higher alkaloid recovery than aqueous extracts in research settings.
How It Works
Mechanism of Action
The primary mechanism of Gloriosa superba's pharmacological activity centers on colchicine and gloriosine binding to soluble αβ-tubulin heterodimers at the colchicine-binding site, preventing GTP-dependent polymerization into microtubules and thereby arresting cell division in metaphase—a mechanism relevant to both its anticancer and anti-inflammatory effects. In inflammatory contexts, colchicine inhibits neutrophil microtubule function, impairing chemotaxis, degranulation, and superoxide production, while also suppressing the NLRP3 inflammasome to reduce IL-1β and IL-18 release. Lipoxygenase inhibition by phenolic and flavonoid fractions reduces leukotriene synthesis from arachidonic acid, contributing to the plant's antipyretic and anti-inflammatory profile, while acetylcholinesterase inhibition by alkaloid fractions prolongs acetylcholine availability at cholinergic synapses, supporting neuroprotective hypotheses. Salicylic acid and benzoic acid present in the rhizome further contribute to cyclooxygenase inhibition, adding a secondary prostaglandin-mediated anti-inflammatory and antipyretic mechanism.
Clinical Evidence
No randomized controlled trials or formal human clinical studies have been conducted on Gloriosa superba extracts as a formulated supplement or therapeutic agent in humans. Available evidence is restricted to in vitro cellular models (MTT cytotoxicity assays, antimicrobial disc diffusion), enzyme inhibition assays, and ethnobotanical surveys. The most quantified outcomes are the anticancer IC₅₀ of 19.52 µg/mL (MDA-MB-231 breast cancer cells) and MRSA inhibition zones of 20 mm, both from laboratory settings that do not directly translate to human therapeutic doses. Confidence in clinical applicability remains very low; pharmaceutical-grade colchicine derived from related Colchicum autumnale has the robust clinical evidence base, but G. superba itself lacks equivalent human study.
Safety & Interactions
Gloriosa superba is highly toxic; ingestion of even small amounts of raw tuber or seed can cause severe colchicine poisoning, presenting as nausea, vomiting, diarrhea, multi-organ failure, bone marrow suppression, alopecia, respiratory failure, and death—fatalities have been reported in children and adults following accidental ingestion. The narrow therapeutic index of colchicine (toxic dose range overlaps closely with therapeutic range) means that whole-plant consumption carries unacceptable risk compared to pharmaceutical-grade colchicine preparations. Critical drug interactions include additive toxicity with P-glycoprotein inhibitors (e.g., cyclosporine, clarithromycin, ketoconazole) and CYP3A4 inhibitors, which elevate plasma colchicine levels; statins combined with colchicine alkaloids increase risk of myopathy. Gloriosa superba is absolutely contraindicated in pregnancy (potent abortifacient documented in traditional and experimental settings), during lactation, in children, and in individuals with renal or hepatic impairment; no safe supplemental dose has been established for human use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Gloriosa superba L.Flame LilyKalihariMora (Malagasy)Ewe aje (Yoruba)AgnishikhaGlory LilyClimbing LilyMalabar Glory Lily
Frequently Asked Questions
Is Gloriosa superba safe to consume or supplement with?
Gloriosa superba is not safe for self-supplementation; the plant's primary alkaloid, colchicine, has a narrow therapeutic index and raw tuber or seed ingestion—even in small amounts—has caused fatal poisoning in adults and children. No safe supplemental dose has been established, and the plant is absolutely contraindicated in pregnancy due to documented abortifacient activity. Any therapeutic application of colchicine should use pharmaceutical-grade preparations under medical supervision.
What is the main active compound in Gloriosa superba and what does it do?
The primary active compound is colchicine, present at 2.12–7.58 mg/g in tubers and up to 0.9% dry weight in seeds. Colchicine binds to αβ-tubulin heterodimers, preventing microtubule polymerization and thereby inhibiting cell division and neutrophil chemotaxis, which underlies both its anticancer and anti-inflammatory pharmacology. Additional alkaloids including gloriosine and 2-desmethyl colchicine contribute structurally similar activities.
What traditional uses does Gloriosa superba have in African medicine?
In African traditional medicine, Gloriosa superba (known as mora in Madagascar and ewe aje in Yoruba practice) is used as an antipyretic to reduce fever, as a topical treatment for head lice (Pediculus humanus capitis), and historically for managing symptoms of gonorrhea. Across sub-Saharan Africa, tuber pastes are applied externally for arthritis and joint inflammation, with healers traditionally recognizing the plant's potency and limiting internal doses carefully.
Does Gloriosa superba have anticancer properties?
In vitro studies show that methanolic seed extracts of Gloriosa superba achieve an IC₅₀ of 19.52 µg/mL against MDA-MB-231 human breast cancer cells in MTT assays, a potency described as comparable to the chemotherapy drug doxorubicin, with 60–80% cancer cell inhibition at 50 µg/mL. This activity is primarily attributed to colchicine's antimitotic mechanism—arresting cell division by binding tubulin dimers. However, no human clinical trials have been conducted, and in vitro results cannot be directly extrapolated to clinical cancer treatment.
How does Gloriosa superba differ from pharmaceutical colchicine?
Pharmaceutical colchicine is a purified, precisely dosed alkaloid (typically 0.5–1.2 mg tablets) extracted and standardized from Colchicum autumnale or Gloriosa superba under controlled manufacturing, with established pharmacokinetic profiles, approved clinical indications (gout, familial Mediterranean fever), and safety monitoring protocols. Gloriosa superba plant material contains variable concentrations of colchicine alongside other alkaloids and phytochemicals, making dose control impossible and toxicity risk substantially higher. Using the plant itself as a substitute for pharmaceutical colchicine is medically inadvisable.
What does clinical research show about Gloriosa superba's effectiveness for fever reduction?
Traditional use of Gloriosa superba for fever across Madagascar and Yoruba medicine is supported by phytochemical evidence showing that its colchicine and salicylic acid content can inhibit prostaglandin synthesis and neutrophil chemotaxis—mechanisms central to fever suppression. However, most supporting evidence comes from in vitro and traditional use documentation rather than large-scale human clinical trials, making it a promising candidate for further investigation rather than a clinically proven treatment. The antipyretic activity has been demonstrated through phytochemical analysis of rhizome extracts, though direct comparative efficacy studies against standard antipyretics are limited.
Who should avoid Gloriosa superba supplementation due to safety concerns?
Pregnant women, nursing mothers, and children should avoid Gloriosa superba entirely, as colchicine is highly toxic to developing fetuses and infants, and safety data in these populations does not exist. Individuals with kidney disease, liver disease, or gastrointestinal disorders should also avoid supplementation, as colchicine accumulates in tissues and can cause severe organ damage at low doses. Anyone taking medications metabolized by the cytochrome P450 system or with a history of colchicine sensitivity should consult a healthcare provider before use.
What forms of Gloriosa superba are used in traditional medicine and how do extraction methods affect activity?
Traditional preparations use dried rhizomes steeped as decoctions or infusions in African herbal medicine, though aqueous and methanolic tuber extracts have demonstrated antibacterial effects in laboratory settings. Extraction method significantly impacts bioavailability and potency—methanolic extracts typically concentrate alkaloids like colchicine more efficiently than water decoctions, though traditional aqueous preparations remain common due to safety considerations around controlling alkaloid dosage. Modern supplemental forms are rarely standardized, making consistency and safety difficult to ensure outside of pharmaceutical-grade preparations.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w gloriosa-superba-flame-lily curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
